 |
 |
Yahoo - Singapore News - Asia Wednesday, February 7 3:31 AM SGT Australia's Bresagen Applies for 2 Int L Cell Therapy Patents SYDNEY, Jan 22 Asia Pulse - Biotech company BresaGen Ltd (ASX:BGN) has filed two international patent applications in cell therapy, marking a signficant advance in its development of treatments for degenerative diseases. BresaGen said that the patent applications are a major addition to the company's intellectual property for cell therapy. The first relates to a novel nerve stem cell and all nervous system cells that differentiate from this stem cell while the second application covers a ectoderm stem cell and claims this cell and cells derived from it such as the skin, cornea, retina of the eye. Cell therapy involves using healthy cells to replace diseased or non-functional cells. BresaGen is targeting Parkinson's Disease for a cell-based therapy and boosted its research in this area with the acquisition in November of a company that specialises in the area, US based CytoGenesis Inc. "Cell therapy is a developing area of medicine, with the potential to provide major new, more effective treatments for a wide range of diseases," BresaGen said in a statement. BresaGen said the patent applications provide the technology for deriving all nerve and surface ectoderm cells to treat neurodegenerative diseases such as Parkinson's; Huntington's Disease; stroke; conditions requiring corneal or lens transplant; and skin grafts for burn victims. At 1449 AEDT BresaGen shares were 10 cents firmer, or 12 per cent, at $1.35. ASIA PULSE http://sg.dailynews.yahoo.com/headlines/asia/asiapulse/article.html?s=singapore/headlines/010207/asia/asiapulse/Australia_s_Bresagen_Applies_for_2_Int_L_Cell_Therapy_Patents.html ***********